Little Green Pharma Ltd. announced its award of a commercial tender to supply CBD50 Classic oils to the highly-regarded French medicinal cannabis trial ("Trial")1, which is currently the Government-led trial in Europe and the only available pathway for the supply of medicinal cannabis in France. The supply price is $77 (EUR 442) per bottle with the total award valued at up to $1.6 million (EUR 1.0 million) subject to Trial demand, which the Company believes will be generated within the remaining March 2024 Trial period. Highlights: LGP awarded commercial tender to supply up to $1.6 Million (EUR 1.0 Million) of its CBD50 product to French medicinal cannabis trial.

LGP remains the supplier with over 85% of the 3,000 participants expected to trial LGP CBD products. LGP is very pleased to be selected by the French Government to continue supplying its GMP manufactured medicinal cannabis products to its French patients, many of whom have been prescribed LGP products since the beginning of the Trial. LGP regards a future French medicinal cannabis market as a highly prospective commercial opportunity for the Company, with the award uniquely positioning LGP to influence and supply a future French medicinal cannabis market upon conclusion of the Trial in March 2024.

Award joins recent tender success. The award joins LGP's recent tender success to supply its CBD1:20 Classic oils to the Trial3 and means LGP will be the primary provider of CBD products to the Trial until its conclusion in March 2024. The prescribing requirements suggest approximatly 85% of the expected 3,000 participants will be prescribed an LGP CBD product, making LGP the most well-known brand by Trial prescribers and patients.

The Company is very pleased to be selected By the French Government to continue supplying the GMP medicinal cannabis oil products to its French patients, Many of whom it has supplied since the beginning of the Trial".